Zhejiang Cheng Yi Pharmaceutical Hits Day High with 7.63% Surge

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 7.63% on March 24, 2026. The stock reached an intraday high of CNY 11.49, reflecting a strong day of trading activity. This performance stands in contrast to the China Shanghai Composite, which saw a modest increase of 1.78% on the same day. Over the past year, Zhejiang Cheng Yi has delivered a robust return of 39.40%, significantly outperforming the broader market, which recorded a return of 15.17%. The company's financial metrics indicate a solid operational foundation, with a return on equity (ROE) of 18.55% and a price-to-book ratio of 3.30. Additionally, the company has reported positive results for the last three consecutive quarters, showcasing a healthy operating cash flow of CNY 308.94 million. Despite some challenges in long-term growth, with net sales and operating profit growing at annual rates of 2.64% and 3.90% respectively over the last five years, Zhejiang Cheng Yi maintains a competitive position within the pharmaceuticals and biotechnology sector. The stock's current dividend yield stands at 1.9%, further enhancing its appeal in the market.